Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Study of SHR0302 in Rheumatoid Arthritis
NCT02665910Phase 1Unknown
- Sponsor
- Hengrui
- Start
- May 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing SHR0302 with Placebo (2 arms). Primary endpoint: Adverse events and the number of volunteers with adverse events. Status: unknown.
02
Drugs
ivarmacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02665910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02665910.